Inge Verbrugge

1.5k total citations
23 papers, 1.1k citations indexed

About

Inge Verbrugge is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Inge Verbrugge has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 13 papers in Oncology and 11 papers in Immunology. Recurrent topics in Inge Verbrugge's work include Cancer Immunotherapy and Biomarkers (7 papers), Cell death mechanisms and regulation (7 papers) and CAR-T cell therapy research (5 papers). Inge Verbrugge is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Cell death mechanisms and regulation (7 papers) and CAR-T cell therapy research (5 papers). Inge Verbrugge collaborates with scholars based in Netherlands, Australia and United States. Inge Verbrugge's co-authors include Ricky W. Johnstone, Mark J. Smyth, Jannie Borst, Maarten Swart, Joost B. Beltman, Marcel Verheij, Hideo Yagita∥, Nicole M. Haynes, Mara Gallí and Jim Hagekyriakou and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Inge Verbrugge

23 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Inge Verbrugge Netherlands 17 621 555 443 122 113 23 1.1k
Julie Stockis Belgium 17 418 0.7× 505 0.9× 589 1.3× 142 1.2× 71 0.6× 21 1.3k
Michela Croce Italy 21 490 0.8× 436 0.8× 510 1.2× 184 1.5× 124 1.1× 47 1.2k
Hong Zheng China 13 569 0.9× 632 1.1× 505 1.1× 179 1.5× 118 1.0× 67 1.4k
Trevor Clancy Norway 18 326 0.5× 439 0.8× 358 0.8× 112 0.9× 95 0.8× 37 891
Elisabetta Fratta Italy 19 457 0.7× 1.1k 2.0× 599 1.4× 250 2.0× 109 1.0× 41 1.5k
Despina S. Kolonias United States 16 576 0.9× 783 1.4× 383 0.9× 97 0.8× 332 2.9× 23 1.5k
Leonardo Mirandola United States 20 439 0.7× 606 1.1× 512 1.2× 98 0.8× 51 0.5× 58 1.1k
Barbara Bodner United States 8 368 0.6× 445 0.8× 280 0.6× 88 0.7× 204 1.8× 9 824
Miriam Redrado Spain 20 518 0.8× 544 1.0× 233 0.5× 270 2.2× 177 1.6× 39 1.1k
Allison R. Greenplate United States 19 465 0.7× 526 0.9× 681 1.5× 178 1.5× 80 0.7× 31 1.3k

Countries citing papers authored by Inge Verbrugge

Since Specialization
Citations

This map shows the geographic impact of Inge Verbrugge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge Verbrugge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge Verbrugge more than expected).

Fields of papers citing papers by Inge Verbrugge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge Verbrugge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge Verbrugge. The network helps show where Inge Verbrugge may publish in the future.

Co-authorship network of co-authors of Inge Verbrugge

This figure shows the co-authorship network connecting the top 25 collaborators of Inge Verbrugge. A scholar is included among the top collaborators of Inge Verbrugge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inge Verbrugge. Inge Verbrugge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Battaglia, Thomas, et al.. (2024). PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice. Journal of Clinical Investigation. 134(6). 14 indexed citations
2.
Matas-Rico, Elisa, Apostolos Menegakis, Maaike van Zon, et al.. (2021). Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells. Cell Reports. 37(7). 110013–110013. 46 indexed citations
3.
Zerp, Shuraila F., et al.. (2020). Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system. Clinical and Translational Radiation Oncology. 24. 1–9. 5 indexed citations
4.
Kroon, Paula, Marit M. van Buuren, Ton N. Schumacher, et al.. (2019). Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity. Cancer Immunology Research. 7(4). 670–682. 41 indexed citations
5.
Kroon, Paula, Jules Gadiot, Alessia Gasparini, et al.. (2016). Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Cancer Immunology Immunotherapy. 65(6). 753–763. 26 indexed citations
6.
Swart, Maarten, Inge Verbrugge, & Joost B. Beltman. (2016). Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Frontiers in Oncology. 6. 233–233. 107 indexed citations
7.
Gadiot, Jules, Ekaterina S. Jordanova, Ruben Lacroix, et al.. (2016). Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. OncoImmunology. 5(12). e1238557–e1238557. 120 indexed citations
8.
Baker, Adele, Gareth P. Gregory, Inge Verbrugge, et al.. (2015). The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. Cancer Research. 76(5). 1158–1169. 83 indexed citations
9.
Verbrugge, Inge, Alessia Gasparini, Nicole M. Haynes, et al.. (2014). The Curative Outcome of Radioimmunotherapy in a Mouse Breast Cancer Model Relies on mTOR Signaling. Radiation Research. 182(2). 219–219. 25 indexed citations
10.
Kooij, Bert van de, Inge Verbrugge, Evert de Vries, et al.. (2013). Ubiquitination by the Membrane-associated RING-CH-8 (MARCH-8) Ligase Controls Steady-state Cell Surface Expression of Tumor Necrosis Factor-related Apoptosis Inducing Ligand (TRAIL) Receptor 1*. Journal of Biological Chemistry. 288(9). 6617–6628. 74 indexed citations
11.
Verbrugge, Inge, Jim Hagekyriakou, Leslie L. Sharp, et al.. (2012). Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies. Cancer Research. 72(13). 3163–3174. 222 indexed citations
12.
Verbrugge, Inge, Mara Gallí, Mark J. Smyth, Ricky W. Johnstone, & Nicole M. Haynes. (2012). Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies. OncoImmunology. 1(9). 1629–1631. 10 indexed citations
13.
Verbrugge, Inge, Ricky W. Johnstone, & Michael Bots. (2011). Promises and challenges of anticancer drugs that target the epigenome. Epigenomics. 3(5). 547–565. 20 indexed citations
14.
Verbrugge, Inge, Ricky W. Johnstone, & Mark J. Smyth. (2010). SnapShot: Extrinsic Apoptosis Pathways. Cell. 143(7). 1192–1192.e2. 81 indexed citations
15.
Maas, Chiel, Inge Verbrugge, Evert de Vries, et al.. (2010). Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation. Cell Death and Differentiation. 17(10). 1613–1623. 32 indexed citations
16.
Verbrugge, Inge, Rogier W. Rooswinkel, Johan Jongsma, et al.. (2009). Combining Radiotherapy with APO010 in Cancer Treatment. Clinical Cancer Research. 15(6). 2031–2038. 23 indexed citations
17.
Verbrugge, Inge, et al.. (2009). Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation. Cell Death and Differentiation. 17(3). 551–561. 20 indexed citations
18.
Weger, Roel A. de, Inge Verbrugge, Annette H. Bruggink, et al.. (2007). Stem cell-derived cardiomyocytes after bone marrow and heart transplantation. Bone Marrow Transplantation. 41(6). 563–569. 14 indexed citations
19.
Verbrugge, Inge, Evert de Vries, Stephen W. G. Tait, et al.. (2007). Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene. 27(5). 574–584. 39 indexed citations
20.
Verbrugge, Inge, Stefan R. Vink, Uta Schaefer, et al.. (2006). TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiotherapy and Oncology. 80(2). 214–222. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie Stockis Breakdown of academic impact, for papers by Michela Croce Breakdown of academic impact, for papers by Hong Zheng Breakdown of academic impact, for papers by Trevor Clancy Breakdown of academic impact, for papers by Elisabetta Fratta Breakdown of academic impact, for papers by Despina S. Kolonias Breakdown of academic impact, for papers by Leonardo Mirandola Breakdown of academic impact, for papers by Barbara Bodner Breakdown of academic impact, for papers by Miriam Redrado Breakdown of academic impact, for papers by Allison R. Greenplate
Rankless by CCL
2026